Skip to main content

Table 3 AHP results - pairwise comparison

From: Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis

MCDA criteria

Indication uniqueness

Disease rarity

Disease severity

Adv.tech.

Manufacturing technology

Therapeutic alternative

Sci. evid. Clin.eff

Benefits from use of medicine (safety aspects)

Cost effectiveness analysis

Budget impact analysis

Therapy cost

HTA recommendations issued elsewhere

Rationali-zation analysis

Indication uniqueness

1

0.763157895

0.828571429

7.25

14.5

0.420289855

0.263636364

0.333333333

0.467741935

0.491525424

0.315217391

0.517857143

1.45

Disease rarity

1.310344828

1

1.085714286

9.5

19

0.550724638

0.345454545

0.436781609

0.612903226

0.644067797

0.413043478

0.678571429

1.9

Disease severity

1.206896552

0.921052632

1

8.75

17.5

0.507246377

0.318181818

0.402298851

0.564516129

0.593220339

0.380434783

0.625

1.75

Adv.tech.

0.137931034

0.105263158

0.114285714

1

2

0.057971014

0.036363636

0.045977011

0.064516129

0.06779661

0.043478261

0.071428571

0.2

Manufacturing technology

0.068965517

0.052631579

0.057142857

0.5

1

0.028985507

0.018181818

0.022988506

0.032258065

0.033898305

0.02173913

0.035714286

0.1

Therapeutic alternative

2.379310345

1.815789474

1.971428571

17.25

34.5

1

0.627272727

0.793103448

1.112903226

1.169491525

0.75

1.232142857

3.45

Sci. evid. Clin.eff

3.793103448

2.894736842

3.142857143

27.5

55

1.594202899

1

1.264367816

1.774193548

1.86440678

1.195652174

1.964285714

5.5

Benefits from use of medicine (safety aspects)

3

2.289473684

2.485714286

21.75

43.5

1.260869565

0.790909091

1

1.403225806

1.474576271

0.945652174

1.553571429

4.35

Cost effectiveness analysis

2.137931034

1.631578947

1.771428571

15.5

31

0.898550725

0.563636364

0.712643678

1

1.050847458

0.673913043

1.107142857

3.1

Budget impact analysis

2.034482759

1.552631579

1.685714286

14.75

29.5

0.855072464

0.536363636

0.67816092

0.951612903

1

0.641304348

1.053571429

2.95

Therapy cost

3.172413793

2.421052632

2.628571429

23

46

1.333333333

0.836363636

1.057471264

1.483870968

1.559322034

1

1.642857143

4.6

HTA recommendations issued elsewhere

1.931034483

1.473684211

1.6

14

28

0.811594203

0.509090909

0.643678161

0.903225806

0.949152542

0.608695652

1

2.8

Rationalization analysis

0.689655172

0.526315789

0.571428571

5

10

0.289855072

0.181818182

0.229885057

0.322580645

0.338983051

0.217391304

0.357142857

1

SUM

22.86206897

17.44736842

18.94285714

165.75

331.5

9.608695652

6.027272727

7.620689655

10.69354839

11.23728814

7.206521739

11.83928571

33.15

  1. Sci. evid. clin.eff Scientific evidence for clinical efficiency, Adv.tech. Advancement of technology
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172